ArticleJournal of pain research2026
Real-World Clinical Outcomes of Polydioxanone Filament Insertion into the Vastus Medialis Obliquus for Knee Osteoarthritis: A Retrospective Observational Study.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: MEST (Muscle Enhancement and Support Therapy) is a device for intramuscular placement of bidirectional barbed polydioxanone filaments. Placement of these filaments into the vastus medialis obliquus has been reported to reduce knee pain and improve quadriceps function in patients with knee osteoarthritis. However, clinical evidence remains limited and is based primarily on a small number of controlled trials in selected populations. This study evaluated the real-world clinical outcomes and safety of the MEST procedure across Kellgren-Lawrence (KL) grades I-IV. Patients and Methods: In this retrospective study, 62 patients with knee osteoarthritis who underwent the MEST procedure between March 2025 and February 2026 were analyzed. Pain intensity, functional outcomes, patient-reported overall improvement, effusion grade, and adverse events were assessed at 4, 8, and 12 weeks. The primary outcome was the change in numeric rating scale (NRS) pain score from baseline to 8 weeks. Factors associated with treatment response, defined as ≥2-point NRS reduction at 8 weeks, were also evaluated by logistic regression. Results: NRS scores decreased from 5.8 ± 1.7 at baseline to 2.5 ± 2.4 at 8 weeks ( Conclusion: The MEST procedure was associated with clinically meaningful pain reduction and favorable patient-reported outcomes across KL grades I-IV, with no serious adverse events. In an exploratory analysis, moderate-to-severe baseline effusion grade was associated with a lower likelihood of response, suggesting that baseline effusion warrants further investigation as a potential marker of treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.